Angray S Kang
Overview
Explore the profile of Angray S Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neunie O, Rabbani W, Baker D, Chambers E, Pfeffer P, Kang A
Hum Antibodies
. 2024 Jun;
32(3):121-128.
PMID: 38905039
Objective: Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have revolutionized treatment...
2.
Baker D, Kang A, Giovannoni G, Schmierer K
Mult Scler Relat Disord
. 2024 Jan;
82:105400.
PMID: 38181696
Neutropenia serves as a risk factor for severe infection and is a consequence of some immune-depleting immunotherapies. This occurs in people with multiple sclerosis following chemotherapy-conditioning in haematopoietic stem cell...
3.
Zaloum S, Wood C, Tank P, Upcott M, Vickaryous N, Anderson V, et al.
Mult Scler
. 2023 Jul;
29(8):979-989.
PMID: 37431627
Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report COVID-19 rates...
4.
Frankling C, Downes M, Kang A, Main E
J Mol Biol
. 2023 May;
435(15):168146.
PMID: 37201677
One infection method widely used by many gram-negative bacteria involves a protein nanomachine called the Type Three Secretion System (T3SS). The T3SS enables the transportation of bacterial "toxins" via a...
5.
Frankling C, Kang A, Main E
Biochemistry
. 2023 Mar;
62(8):1420-1427.
PMID: 36996474
The type III secretion system is a large multiprotein complex that many Gram-negative bacteria use for infection. A crucial part of the complex is its translocon pore formed by two...
6.
Baker D, Forte E, Pryce G, Kang A, James L, Giovannoni G, et al.
Mult Scler Relat Disord
. 2022 Dec;
69:104425.
PMID: 36470168
Background: Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-mediated lymphocyte migration, lesion formation and positively-impacts on active multiple sclerosis (MS). These S1PR modulatory drugs have different: European Union use restrictions, pharmacokinetics,...
7.
Tallantyre E, Scurr M, Vickaryous N, Richards A, Anderson V, Baker D, et al.
Mult Scler Relat Disord
. 2022 Jun;
64:103937.
PMID: 35700625
Background: People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine...
8.
Baker D, MacDougall A, Kang A, Schmierer K, Giovannoni G, Dobson R
Clin Exp Immunol
. 2022 May;
207(3):263-271.
PMID: 35553629
Although there is an ever-increasing number of disease-modifying treatments for relapsing multiple sclerosis (MS), few appear to influence coronavirus disease 2019 (COVID-19) severity. There is concern about the use of...
9.
Baker D, MacDougall A, Kang A, Schmierer K, Giovannoni G, Dobson R
Mult Scler Relat Disord
. 2021 Dec;
57:103448.
PMID: 34902760
Background: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging...
10.
Tallantyre E, Vickaryous N, Anderson V, Asardag A, Baker D, Bestwick J, et al.
Ann Neurol
. 2021 Oct;
91(1):89-100.
PMID: 34687063
Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple...